21.37
0.38 (1.81%)
| Previous Close | 20.99 |
| Open | 21.00 |
| Volume | 660,828 |
| Avg. Volume (3M) | 777,225 |
| Market Cap | 1,745,124,864 |
| Price / Sales | 5.38 |
| Price / Book | 5.31 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -130,369.45% |
| Diluted EPS (TTM) | -3.35 |
| Total Debt/Equity (MRQ) | 3.82% |
| Current Ratio (MRQ) | 19.49 |
| Operating Cash Flow (TTM) | -279.75 M |
| Levered Free Cash Flow (TTM) | -171.41 M |
| Return on Assets (TTM) | -32.62% |
| Return on Equity (TTM) | -51.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Viridian Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 114.61% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Novo Holdings A/S | 30 Jun 2025 | 2,380,000 |
| Maverick Capital Ltd | 30 Jun 2025 | 2,257,010 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 41.00 (RBC Capital, 91.86%) | Buy |
| Median | 32.00 (49.74%) | |
| Low | 26.00 (Wells Fargo, 21.67%) | Hold |
| Average | 32.60 (52.55%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 16.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 07 Aug 2025 | 30.00 (40.38%) | Buy | 16.53 |
| Oppenheimer | 07 Aug 2025 | 32.00 (49.74%) | Buy | 16.53 |
| RBC Capital | 07 Aug 2025 | 41.00 (91.86%) | Buy | 16.53 |
| Wells Fargo | 07 Aug 2025 | 26.00 (21.67%) | Hold | 16.53 |
| Needham | 06 Aug 2025 | 34.00 (59.10%) | Buy | 17.20 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |